Resistance to antibiotics: Are we in the post-antibiotic era?

被引:915
作者
Alanis, AJ [1 ]
机构
[1] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
antibiotic resistance; bacterial resistance; new antibiotics; antibiotic research;
D O I
10.1016/j.arcmed.2005.06.009
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Serious infections caused by bacteria that have become resistant to commonly used antibiotics have become a major global healthcare problem in the 21st century. They not only are more severe and require longer and more complex treatments, but they are also significantly more expensive to diagnose and to treat. Antibiotic resistance, initially a problem of the hospital setting associated with an increased number of hospital-acquired infections usually in critically ill and immunosuppressed patients, has now extended into the community causing severe infections difficult to diagnose and treat. The molecular mechanisms by which bacteria have become resistant to antibiotics are diverse and complex. Bacteria have developed resistance to all different classes of antibiotics discovered to date. The most frequent type of resistance is acquired and transmitted horizontally via the conjugation of a plasmid. In recent times new mechanisms of resistance have resulted in the simultaneous development of resistance to several antibiotic classes creating very dangerous multidrug-resistant (MDR) bacterial strains, some also known as "superbugs". The indiscriminate and inappropriate use of antibiotics in outpatient clinics, hospitalized patients and in the food industry is the single largest factor leading to antibiotic resistance. In recent years, the number of new antibiotics licensed for human use in different parts of the world has been lower than in the recent past. In addition, there has been less innovation in the field of antimicrobial discovery research and development. The pharmaceutical industry, large academic institutions or the government are not investing the necessary resources to produce the next generation of newer safe and effective antimicrobial drugs. In many cases, large pharmaceutical companies have terminated their anti-infective research programs altogether due to economic reasons. The potential negative consequences of all these events are relevant because they put society at risk for the spread of potentially serious MDR bacterial infections. (c) 2005 IMSS. Published by Elsevier Inc.
引用
收藏
页码:697 / 705
页数:9
相关论文
共 74 条
[1]   Pneumococcal resistance in perspective: how well are we combating it? [J].
Amsden, GW .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (02) :S125-S128
[2]   Mechanisms of fungal resistance - An overview [J].
Balkis, MM ;
Leidich, SD ;
Mukherjee, PK ;
Ghannoum, MA .
DRUGS, 2002, 62 (07) :1025-1040
[3]   The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens [J].
Cizman, M ;
Pokorn, M ;
Seme, K ;
Orazem, A ;
Paragi, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (04) :475-477
[4]   A novel approach to preventing insect-borne diseases [J].
Conte, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :785-786
[5]   Vancomycin-resistant enterococci - A road map on how to prevent the emergence and transmission of antimicrobial resistance [J].
DeLisle, S ;
Perl, TM .
CHEST, 2003, 123 (05) :504S-518S
[6]   Methicillin-resistant Staphylococcus aureus:: An evolutionary, epidemiologic, and therapeutic odyssey [J].
Deresinski, S .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (04) :562-573
[7]   Viral resistance to chemotherapeutic agents: An expectable unexpected phenomenon [J].
Dianzani, F .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2003, 35 :6-7
[8]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[9]   COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].
DIMASI, JA ;
HANSEN, RW ;
GRABOWSKI, HG ;
LASAGNA, L .
JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) :107-142
[10]   Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. [J].
Donskey, CJ ;
Chowdhry, TK ;
Hecker, MT ;
Hoyen, CK ;
Hanrahan, JA ;
Hujer, AM ;
Hutton-Thomas, RA ;
Whalen, CC ;
Bonomo, RA ;
Rice, LB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1925-1932